Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Tax Provisions (2018 - 2025)

Marimed has reported Tax Provisions over the past 8 years, most recently at -$2.7 million for Q4 2025.

  • Quarterly Tax Provisions fell 154.3% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 55.95% year-over-year, with the annual reading at $3.6 million for FY2025, 55.95% down from the prior year.
  • Tax Provisions was -$2.7 million for Q4 2025 at Marimed, down from $2.8 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $7.2 million in Q4 2021 and troughed at -$2.7 million in Q4 2025.
  • The 5-year median for Tax Provisions is $2.2 million (2022), against an average of $2.2 million.
  • Year-over-year, Tax Provisions surged 9214.56% in 2021 and then plummeted 154.3% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $7.2 million in 2021, then tumbled by 127.83% to -$2.0 million in 2022, then skyrocketed by 124.97% to $498000.0 in 2023, then surged by 893.57% to $4.9 million in 2024, then plummeted by 154.3% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Tax Provisions are -$2.7 million (Q4 2025), $2.8 million (Q3 2025), and $691000.0 (Q2 2025).